Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses molecular profiling in the treatment of colorectal cancer (CRC).
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School elaborates on the efficacy and safety of combination eribulin and pembrolizumab in metastatic breast cancer.
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether the drug is showing promise as a treatment for MM.
Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne provides insight on KEYNOTE-048 investigating pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma.
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, describes the unmet medical needs in treating non-small cell lung cancer (NSCLC)
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC).
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center discusses the value of liquid biopsy and where it is ready for routine practice in CRC.
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides results from the ECOG trial in smoldering multiple myeloma (MM).
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center addresses on the future of non-small cell lung cancer (NSCLC) drug development.